Swedish to advance personalized medicine program
The Swedish Cancer Institute (SCI) will advance its Personalized Medicine Program with the adoption of Syapse Precision Medicine Platform.
The software package will mine SCI's EHR and genomic records to match patients' genetic mutations to treatments most appropriate to their tumors.
The Personalized Medicine Program, launched in April 2014, combines advanced treatments based on the “molecular fingerprint” of a tumor with individualized emotional and physical supportive care, according to a release. SCI’s gene alteration panel, developed in partnership with CellNetix Pathology & Laboratories, is based on a focused set of gene alterations that are most relevant to cancer treatments. By combining gene alteration data with the clinical decision support of the Syapse platform, patients may receive tailored therapies or targeted clinical trials specific to their molecular fingerprint instead of treatments based solely on the origin of their cancer.
Editor
Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.